Levetiracetam Tablet
Product Images NDC 55111-181

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55111-181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Levetiracetam Tablets USP, 250 mg oral tablets by Dr. Reddy's Laboratories Limited. The label indicates each unit-dose package contains 10 tablets (1 blister card containing 10 tablets). Storage instructions, dosage recommendation to see the package insert, and a pharmacist attention notice are included. The label also displays the NDC number and manufacturing address in India.*

FDA Label Image

Carton2 (Carton2)

Levetiracetam Tablets USP, 500 mg oral tablets packaging from Dr. Reddy's Laboratories Limited. The label shows a 10-tablet unit-dose blister card inside a carton with product storage instructions, dosage guidance reference, and manufacturer information. The packaging is primarily white with blue and red text accents.*

FDA Label Image

Carton3 (Carton3)

Levetiracetam Tablets USP, 750 mg oral tablets packaging label from Dr. Reddy's Laboratories Limited. The label indicates a 10 unit-dose tablet carton (1 blister card containing 10 tablets) with storage instructions and a note that the unit-dose package is not child-resistant. The label includes manufacturer details and an NDC number.*

FDA Label Image

Container1 (Container1)

Levetiracetam Tablets USP 250 mg oral tablets label from Dr. Reddy's Laboratories Limited. The label indicates a bottle of 120 tablets and includes a pharmacist warning to provide the Medication Guide to patients. Storage instructions and manufacturer details are printed alongside the NDC code 55111-181-04.*

FDA Label Image

Container2 (Container2)

Label for Levetiracetam Tablets USP 500 mg, an oral tablet medication by Dr. Reddy's Laboratories Limited. The label indicates a package containing 120 tablets. It includes the National Drug Code (NDC) 55111-182-04 and a red box warning pharmacists to ensure patients receive the accompanying medication guide. Additional storage and dispensing instructions are also printed on the label along with batch and expiration information areas.*

FDA Label Image

Container3 (Container3)

Levetiracetam Tablets USP 750 mg oral tablets in a container labeled by Dr. Reddy's Laboratories Limited. The label includes the NDC 55111-183-04, states the quantity as 120 tablets, and provides storage and handling instructions, such as protecting the tablets from light and keeping them at controlled room temperature.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 30.6% for Levetiracetam 3000 mg/day.*

FDA Label Image

Figure2 (Figure2)

Bar graph comparing seizure rates among patients taking placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The graph shows seizure rates of 6.3% for placebo (N=111), 20.8% for Levetiracetam 1000 mg/day (N=106), and 35.2% for Levetiracetam 2000 mg/day (N=206), with seizure rate percentages labeled above each bar.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing the number of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The chart shows the Placebo group with 14.4% and the Levetiracetam group with 39.4%, with the Y-axis labeled as number of patients.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients between a placebo group (N=97) and a Levetiracetam group (N=101). The Levetiracetam group shows a higher percentage at 44.6% compared to 19.6% for the placebo group.*

FDA Label Image

Figure5 (Figure5)

A bar chart comparing the percentage of patients in two groups: Placebo (N=51) and Levetiracetam (N=58). The Placebo group shows 19.6%, and the Levetiracetam group shows 43.1%. The chart visually indicates a higher percentage in the Levetiracetam group.*

FDA Label Image

Figure6 (Figure6)

A bar graph comparing the percentage of patients between a placebo group (N=84) and a Levetiracetam group (N=79). The graph shows 45.2% for the placebo group and 72.2% for the Levetiracetam group, with an asterisk indicating statistical significance.*

FDA Label Image

Structure (Structure)

Chemical structure of Levetiracetam, the active ingredient in the product. The structure shows a pyrrolidone ring with attached ethyl and amide groups, consistent with the molecular representation of Levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.